Andrew J. Schwab's most recent trade in Skye Bioscience Inc was a trade of 35,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Skye Bioscience Inc | Schwab Andrew J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Skye Bioscience Inc | Andrew J. Schwab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.60 per share. | 11 Sep 2024 | 214,556 | 8,178,964 (6%) | 0% | 6.6 | 1,416,070 | Common Stock |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.60 per share. | 11 Sep 2024 | 36,504 | 1,681,685 (1%) | 0% | 6.6 | 240,926 | Common Stock |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.06 per share. | 11 Sep 2024 | 11,758 | 8,167,206 (6%) | 0% | 6.1 | 71,253 | Common Stock |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.06 per share. | 11 Sep 2024 | 2,000 | 1,679,685 (1%) | 0% | 6.1 | 12,120 | Common Stock |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.60 per share. | 11 Sep 2024 | 1,440 | 66,356 (0%) | 0% | 6.6 | 9,504 | Common Stock |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.06 per share. | 11 Sep 2024 | 79 | 66,277 (0%) | 0% | 6.1 | 479 | Common Stock |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 10.00 per share. | 13 Mar 2024 | 450,000 | 8,393,520 (6%) | 0% | 10 | 4,500,000 | Common Stock |
| Enliven Therapeutics Inc | Andrew J. Schwab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,838,092 | 4,838,092 | - | - | Common Stock | |
| Enliven Therapeutics Inc | Andrew J. Schwab | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 960,383 | 960,383 | - | - | Common Stock | |
| Enliven Therapeutics Inc | Andrew J. Schwab | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 27,567 | 27,567 | - | - | Stock Option (right to buy) |